Compare Globus Medical Inc. Class A Common Stock (GMED) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs State Street SPDR S&P Homebuilders ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while State Street SPDR S&P Homebuilders ETF trades at $92.84 (market cap $1.49B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 6.9× State Street SPDR S&P Homebuilders ETF's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and State Street SPDR S&P Homebuilders ETF for 35 Days on average.
| GMED | XHB | |
|---|---|---|
Market Cap | $10.25B | $1.49B |
Volume | 1,108,124 | 1,578,908 |
Sector | Health | Broad Market / Factor |
52-Week High | $96.82 | $121.36 |
52-Week Low | $58.33 | $92.84 |
Typical Hold Time | 0 Days | 35 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
XHB, the SPDR S&P Homebuilders ETF, trades at $94.70, up 0.69% on the day, but technical indicators signal a bearish trend with moving averages and overall momentum pointing lower. Recent news highlights mixed housing data, with rising mortgage rates pressuring the sector but new legislation and institutional interest offering potential support. The ETF lacks current fundamental ratio data but tracks homebuilder stocks sensitive to economic cycles.
The outlook for XHB hinges on housing market dynamics; opportunities exist if affordability improves or construction accelerates, but risks include persistent high rates and economic slowdowns. Investor sentiment is cautious amid volatile home sales data, requiring close watch on macroeconomic indicators for directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
